Shuttle Pharmaceuticals Announces Material Agreement
Ticker: SHPH · Form: 8-K · Filed: Nov 1, 2024 · CIK: 1757499
| Field | Detail |
|---|---|
| Company | Shuttle Pharmaceuticals Holdings, Inc. (SHPH) |
| Form Type | 8-K |
| Filed Date | Nov 1, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.00001, $1.525, $1, $0.001, $1.40 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, regulation-fd, financials
TL;DR
Shuttle Pharma signed a big deal on Oct 31st, filing shows.
AI Summary
On October 31, 2024, Shuttle Pharmaceuticals Holdings, Inc. announced a material definitive agreement related to its operations. The company also disclosed information under Regulation FD and filed financial statements and exhibits. The earliest event reported was on October 29, 2024.
Why It Matters
This filing indicates a significant business development for Shuttle Pharmaceuticals, potentially impacting its strategic direction and financial future.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the specifics of this agreement are not yet fully detailed in the provided text.
Key Players & Entities
- Shuttle Pharmaceuticals Holdings, Inc. (company) — Registrant
- October 31, 2024 (date) — Date of Report
- October 29, 2024 (date) — Earliest Event Reported
- Delaware (jurisdiction) — State of Incorporation
- Gaithersburg, MD (location) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement announced by Shuttle Pharmaceuticals?
The provided text states that Shuttle Pharmaceuticals Holdings, Inc. entered into a material definitive agreement, but the specific details of the agreement are not disclosed in this excerpt.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on October 29, 2024.
What is Shuttle Pharmaceuticals Holdings, Inc.'s principal executive office address?
Shuttle Pharmaceuticals Holdings, Inc.'s principal executive office is located at 401 Professional Drive, Suite 260, Gaithersburg, MD 20879.
What is the standard industrial classification for Shuttle Pharmaceuticals Holdings, Inc.?
The standard industrial classification for Shuttle Pharmaceuticals Holdings, Inc. is Pharmaceutical Preparations [2834].
What is the fiscal year end for Shuttle Pharmaceuticals Holdings, Inc.?
The fiscal year end for Shuttle Pharmaceuticals Holdings, Inc. is December 31.
Filing Stats: 1,780 words · 7 min read · ~6 pages · Grade level 11.5 · Accepted 2024-10-31 20:57:31
Key Financial Figures
- $0.00001 — ange on which registered Common Stock $0.00001 per share SHPH The Nasdaq Stock Mar
- $1.525 — and one accompanying Common Warrant was $1.525. The public offering price of each Pre-
- $1 — and one accompanying Common Warrant was $1.524, which equals the price at which on
- $0.001 — d to the public in this offering, minus $0.001. The exercise price of each Pre-Funded
- $1.40 — has an initial exercise price equal to $1.40. The Company received aggregate gross
- $4.5 m — eeds from the Offering of approximately $4.5 million, before deducting placement agent
- $2.3 million — ls of its product candidates, including $2.3 million in payments that will be owed to Therad
- $100,000 — the offering in an amount not to exceed $100,000 and up to $50,000 for certain reasonabl
- $50,000 — amount not to exceed $100,000 and up to $50,000 for certain reasonable non-accountable
Filing Documents
- form8-k.htm (8-K) — 58KB
- ex1-1.htm (EX-1.1) — 71KB
- ex4-1.htm (EX-4.1) — 116KB
- ex4-2.htm (EX-4.2) — 111KB
- ex10-1.htm (EX-10.1) — 290KB
- ex99-1.htm (EX-99.1) — 12KB
- 0001493152-24-043249.txt ( ) — 964KB
- shph-20241031.xsd (EX-101.SCH) — 3KB
- shph-20241031_lab.xml (EX-101.LAB) — 33KB
- shph-20241031_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Dated: October 31, 2024 By: /s/ Anatoly Dritschilo Name: Anatoly Dritschilo Title: Chief Executive Officer